Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (495,761)	$ (375,014)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	73,541	64,267
Loss on disposal of property, plant and equipment	2,083	928
Unrealized loss on equity investments	3,497	1,937
Deferred tax benefit	(9,346)	(248,716)
Stock-based compensation	160,906	197,180
Post-combination expense for acceleration of unvested equity	0	80,960
Realized (gain) loss on preferred stock investment	10,000	(30,500)
Amortization of deferred financing costs, convertible note debt discount and issuance costs, and other liabilities	5,273	4,948
Amortization of premium on short-term investments	1,795	3,265
Amortization of acquired intangible assets	74,536	70,954
Impairment of long-lived assets	12,537	20,210
Asset acquisition IPR&D expense	0	85,337
Loss on sale of asset	13,244	0
Remeasurement of contingent consideration	(57,619)	10,986
Non-cash lease expense	24,452	18,347
Changes in assets and liabilities:
Accounts receivable, net	27,968	(14,038)
Inventory, net	(9,705)	(1,091)
Operating lease liabilities	(16,242)	(11,834)
Accounts payable and accrued liabilities	(89,268)	64,344
Other assets and liabilities	(7,487)	(20,134)
Net cash used in operating activities	(275,596)	(77,664)
Cash flows from investing activities:
Purchases of marketable securities	(102,438)	(1,021,557)
Maturities and sales of marketable securities	377,440	424,830
Purchases of property, plant and equipment	(141,586)	(76,374)
Proceeds from sale of asset	25,000	0
Business combination, net of cash acquired and issuance costs	685	(415,549)
Asset acquisition	0	(58,073)
Investments in privately held companies	(26,827)	(13,555)
Other investing activities	(49)	(244)
Net cash provided by (used in) investing activities	132,225	(1,160,522)
Cash flows from financing activities:
Proceeds from accounts receivable securitization facility	50,000	0
Proceeds from exercise of common stock options	5,966	13,372
Proceeds in connection with the Company’s employee stock purchase plan	15,529	12,038
Other financing activities	(5,113)	(4,742)
Net cash provided by financing activities	66,382	20,668
Effects of exchange rate changes on cash and cash equivalents	(3,176)	0
Net decrease in cash, cash equivalents and restricted cash	(80,165)	(1,217,518)
Cash, cash equivalents and restricted cash, beginning of period	315,768	1,491,594
Cash, cash equivalents and restricted cash, end of period	235,603	274,076
Supplemental disclosure of non-cash investing and financing activities
Property, plant and equipment acquired but not paid	23,659	21,110
Business combination contingent consideration liability	4,600	350,348
Supplemental disclosure of cash flow information:
Interest paid	10,754	10,685
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	235,306	273,779
Restricted cash — included in prepaid expenses and other current assets as of September 30, 2022, and other long-term assets, net as of September 30, 2021	297	297
Total cash, cash equivalents and restricted cash	$ 235,603	$ 274,076